Lirioresinol B dimethyl ether

Lirioresinol B dimethyl ether is a lignan originally isolated from L. tulipifera that has diverse biological activities.^1,2,3,4 It scavenges DPPH (Item No. 14805) radicals in a cell-free assay (IC₅₀ = 110.9 µM) and reduces the levels of NF-κB and COX-2 in HepG2 hepatocellular carcinoma cells when used at a concentration of 40 µM.² Lirioresinol B dimethyl ether (50 mg/kg per day) also reduces intratumoral levels of NF-κB and COX-2 in a mouse model of hepatocellular carcinoma induced by carbon tetrachloride (CCl₄) and diethylnitrosamine (DEN). It reduces liver damage and improves hepatic function in mice in the same model. Lirioresinol B dimethyl ether (40 and 80 µM) reduces the production of parathyroid hormone-related protein (PTHrP) in MDA-MB-231 breast cancer cells and inhibits RANKL-induced differentiation of bone marrow-derived macrophages (BMDMs; IC₅₀ = 8.88 µM).³ Lirioresinol B dimethyl ether is also active against L. amazonensis and L. braziliensis intracellular amastigotes (IC₅₀s = 43.9 and 76 µM, respectively).⁴

WARNING This product is not for human or veterinary use.

1. Dickey, E.E. Liriodendrin, a new lignan diglucoside from the inner bark of yellow poplar (Liriodendron tulipifera L.). The Journal of Organic Chemistry 23(2), 179-184 (1958).

2. Shehzad, A., Rehmat, S., Ul-Islam, S., et al. Lirioresinol B dimethyl ether inhibits NF-κB and COX-2 and activates IκBα expression in CCl4-induced hepatic fibrosis. BMC Complement Med. Ther. 20(1), 49 (2020).

3. Jun, A.Y., Kim, H.-J., Park, K.-K., et al. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts. Invest. New Drugs 32(1), 1-13 (2014).

4. Rebouças-Silva, J., Santos, G.F., Filho, J.M.B., et al. In vitro leishmanicidal effect of Yangambin and Epi-yangambin lignans isolated from Ocotea fasciculata (Nees) Mez. Front Cell. Infect. Microbiol. 12, 1045732 (2022).